Champions Oncology Q1 record revenue $13.7M (+22% YoY); adjusted EBITDA $450K

CHAMPIONS ONCOLOGY, INC.

2023-Q1 EPS reported -$0.02 revenue$13,745,000

Record quarterly revenue $13.7M, up 22% from $11.3M in prior year quarter.
Adjusted EBITDA $450K vs $422K; operating loss $284K includes $206K stock comp and $528K D&A.
Gross margin 49% vs 52% due to higher study expenses and SaaS costs; bookings at record level.
Cash $8.1M, no debt; net cash used in ops $195K, investing $754K for lab equipment.
Alloy Therapeutics partnership delivered series of antibody hits.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.